1Sadagurski M, Norquay L, Farhang J, et al. Human IL6 enhances leptin action in Mice[J]. Diabetologia,2010,53(3):525-535.
2Carey AL, Steinberg GR, Macaulay SL, et al. Interleukin-6 increas- es insulin-stimulated glucose disposal in humans and glucose up- take and fatty acid oxidation in vitro via AMP-activated proteinki- nase[J].Diabetes,2006,55(10):2688-2697.
3Oganes A,Jamshid T. The role of magnetic resonance imaging in the early diagnosis of rheumatoid arthritis[J]. Top Magn Reson Imaging, 2007,18(2) : 169-176.
4Shiozawa S, Tsumiyama K. Pathogenesis of rheumatoid arthritis and c-Fos/AP-1 [J]. Cell Cycle, 2009,15(8):1539-15d3.
5Curtis JR, Singh JA. Use of biologics in rheumatoid arthritis: current and emerging paradigms of care[J]. Clin Therap, 2011, 33(6)- 679-707.
6Nishimoto N, Kanakura Y, Aozasa K, et al. Humanized anti-inter leukin-6 receptor antibody treatment of multieentric Castleman dis- eas[J]. Blood, 2005, 106(8):2627-2632.
7Yang Z, Feng J, Li Y, et al. Structure-based design and character- ization of a novel IL-6 antagonist peptide[J]. Mol Immunol,2005,42 (9):1015-1021.
8Greten FR, ArkanMC, Bollrath J,et al. NF-KB is a negative regula- tor of IL-lbeta secretion as revealed by genetic and pharmacologi- cal inhibition of IKKbeta[J].Cell, 2007, 130(5): 918-931.
9MURAKAMI M,NISHIMOTO N.The value of blocking IL-6 outside of rheumatoid arthritis:current perspective[J].Current Opinion in Rheumatology,2011,23(3):273-277.
10AREND W P.The balance between IL-1 and IL-1Ra in disease[J].Cytokine&Growth Factor Reviews,2002,13(4):323-340.
